Can exercise ease chemo nerve damage? new trial tests shorter programme
NCT ID NCT07307690
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares an 8-week versus a 12-week supervised exercise programme in 50 colorectal cancer patients receiving chemotherapy. The goal is to see if exercise can reduce chemotherapy-induced peripheral neuropathy—nerve damage causing tingling, numbness, and pain—and improve quality of life. Participants will do two 50-minute sessions per week with a physiotherapist, including strength and flexibility exercises.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
supervised physical exercise programme
What this could lead to
If it works, this could show that a shorter 8-week exercise programme is as effective as a 12-week one for reducing nerve pain and improving daily life.
What could go wrong
This is a small, early-stage trial with only 50 participants, so results may not apply to all patients. Exercise might not reduce nerve symptoms for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••